Allergy Asthma Immunol Res.  2019 Mar;11(2):188-200. 10.4168/aair.2019.11.2.188.

Update on the Management of Occupational Asthma and Work-Exacerbated Asthma

• Lau A
• Tarlo SM

• KMID: 2431851
• DOI: http://doi.org/10.4168/aair.2019.11.2.188

Abstract

Work-related asthma is the most common occupational lung disease encountered in clinical practice. In adult asthmatics, work-relatedness can account for 15%-33% of cases, but delays in diagnosis remain common and lead to worse outcomes. Accurate diagnosis of asthma is the first step to managing occupational asthma, which can be sensitizer-induced or irritant-induced asthma. While latency has traditionally been recognized as a hallmark of sensitizer-induced asthma and rapid-onset a defining feature of irritant-induced asthma (as in Reactive Airway Dysfunction Syndrome), there is epidemiological evidence for irritant-induced asthma with latency from chronic moderate exposure. Diagnostic testing while the patient is still in the workplace significantly improves sensitivity. While specific inhalational challenges remain the gold-standard for the diagnosis of occupational asthma, they are not available outside of specialized centers. Commonly available tests including bronchoprovocation challenges and peak flow monitoring are important tools for practicing clinicians. Management of sensitizer-induced occupational asthma is notable for the central importance of removal from the causative agent: ideally, removal of the culprit agent; but if not feasible, this may require changes in the work process or ultimately, removal of the worker from the workplace. While workers' compensation programs may reduce income loss, these are not universal and there can be significant socio-economic impact from work-related asthma. Primary prevention remains the preferred method of reducing the burden of occupational asthma, which may include modification to work processes, better worker education and substitution of sensitizing agents from the workplace with safer compounds.

Keyword

Asthma; asthma, occupational; case management

MeSH Terms

Adult
Asthma*
Asthma, Occupational*
Case Management
Diagnosis
Diagnostic Tests, Routine
Education
Humans
Lung Diseases
Methods
Primary Prevention
Workers' Compensation

Reference

1. Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med. 2014; 370:640–649.

2. Paris C, Ngatchou-Wandji J, Luc A, McNamee R, Bensefa-Colas L, Larabi L, et al. Work-related asthma in France: recent trends for the period 2001–2009. Occup Environ Med. 2012; 69:391–397.

3. Ribeiro M, Tarlo SM, Czyrka A, Vernich L, Luce CE, Liss GM. Diisocyanate and non-diisocyanate sensitizer-induced occupational asthma frequency during 2003 to 2007 in Ontario, Canada. J Occup Environ Med. 2014; 56:1001–1007.

4. Walters GI, Kirkham A, McGrath EE, Moore VC, Robertson AS, Burge PS. Twenty years of SHIELD: decreasing incidence of occupational asthma in the West Midlands, UK? Occup Environ Med. 2015; 72:304–310.

5. Suojalehto H, Karvala K, Ahonen S, Ylinen K, Airaksinen L, Suuronen K, et al. 3-(Bromomethyl)-2-chloro-4-(methylsulfonyl)- benzoic acid: a new cause of sensitiser induced occupational asthma, rhinitis and urticaria. Occup Environ Med. 2018; 75:277–282.

6. Cartier A. New causes of immunologic occupational asthma, 2012–2014. Curr Opin Allergy Clin Immunol. 2015; 15:117–123.

7. Cannon J, Fitzgerald B, Seed M, Agius R, Jiwany A, Cullinan P. Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR. Occup Med (Lond). 2015; 65:256–258.

8. Walters GI, Robertson AS, Moore VC, Burge PS. Occupational asthma caused by sensitization to a cleaning product containing triclosan. Ann Allergy Asthma Immunol. 2017; 118:370–371.

9. Mazurek JM, White GE. Centers for Disease Control and Prevention (CDC). Work-related asthma—22 states, 2012. MMWR Morb Mortal Wkly Rep. 2015; 64:343–346.

10. Dodd KE, Mazurek JM. Asthma medication use among adults with current asthma by work-related asthma status, Asthma Call-back Survey, 29 states, 2012–2013. J Asthma. 2018; 55:364–372.

11. Bradshaw L, Sumner J, Delic J, Henneberger P, Fishwick D. Work aggravated asthma in Great Britain: a cross-sectional postal survey. Prim Health Care Res Dev. 2018.

12. Lim T, Liss GM, Vernich L, Buyantseva L, Tarlo SM. Work-exacerbated asthma in a workers' compensation population. Occup Med (Lond). 2014; 64:206–210.

13. Gotzev S, Lipszyc JC, Connor D, Tarlo SM. Trends in occupations and work sectors among patients with work-related asthma at a Canadian tertiary care clinic. Chest. 2016; 150:811–818.

14. Henneberger P, Liang X, Lemière C. A comparison of work-exacerbated asthma cases from clinical and epidemiological settings. Can Respir J. 2013; 20:159–164.

15. Tarlo SM, Chan-Yeung M. Importance of definitions and population selection in work-related asthma. Can Respir J. 2013; 20:156.

16. Tarlo SM, Balmes J, Balkissoon R, Beach J, Beckett W, Bernstein D, et al. Diagnosis and management of work-related asthma: American College of Chest Physicians Consensus Statement. Chest. 2008; 134:1S–41S.

17. Nicholson PJ, Cullinan P, Taylor AJ, Burge PS, Boyle C. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med. 2005; 62:290–299.

18. Newman Taylor AJ, Cullinan P, Burge PS, Nicholson P, Boyle C. BOHRF guidelines for occupational asthma. Thorax. 2005; 60:364–366.

19. Henneberger PK. Work-exacerbated asthma. Curr Opin Allergy Clin Immunol. 2007; 7:146–151.

20. Tarlo SM. Management and prevention of occupational asthma. Minerva Med. 2017; 108:229–238.

21. Vandenplas O, Suojalehto H, Cullinan P. Diagnosing occupational asthma. Clin Exp Allergy. 2017; 47:6–18.

22. Santos MS, Jung H, Peyrovi J, Lou W, Liss GM, Tarlo SM. Occupational asthma and work-exacerbated asthma: factors associated with time to diagnostic steps. Chest. 2007; 131:1768–1775.

23. Walters GI, Soundy A, Robertson AS, Burge PS, Ayres JG. Understanding health beliefs and behaviour in workers with suspected occupational asthma. Respir Med. 2015; 109:379–388.

24. Walters GI, McGrath EE, Ayres JG. Audit of the recording of occupational asthma in primary care. Occup Med (Lond). 2012; 62:570–573.

25. Ellis PR, Walters GI. Missed opportunities to identify occupational asthma in acute secondary care. Occup Med (Lond). 2018; 68:56–59.

26. Mazurek JM, White GE, Moorman JE, Storey E. Patient-physician communication about work-related asthma: what we do and do not know. Ann Allergy Asthma Immunol. 2015; 114:97–102.

27. Ghajar-Khosravi S, Tarlo SM, Liss GM, Chignell M, Ribeiro M, Levinson AJ, et al. Development of a web-based, work-related asthma educational tool for patients with asthma. Can Respir J. 2013; 20:417–423.

28. Lipszyc JC, Gotzev S, Scarborough J, Liss GM, Gupta S, Tarlo SM. Evaluation of the efficacy of a web-based work-related asthma educational tool. J Asthma. 2016; 53:1071–1075.

29. Killorn KR, Dostaler SM, Olajos-Clow J, Turcotte SE, Minard JP, Holness DL, et al. The development and test re-test reliability of a work-related asthma screening questionnaire. J Asthma. 2015; 52:279–288.

30. Harber P, Redlich CA, Hines S, Filios MS, Storey E. Recommendations for a clinical decision support system for work-related asthma in primary care settings. J Occup Environ Med. 2017; 59:e231–e235.

31. Baur X, Bakehe P. Allergens causing occupational asthma: an evidence-based evaluation of the literature. Int Arch Occup Environ Health. 2014; 87:339–363.

32. Beach J, Rowe BH, Blitz S, Crumley E, Hooton N, Russell K, et al. Number 129. Diagnosis and management of work-related asthma. AHRQ publication number 06-E003-1. United States Agency for Healthcare Research and Quality. AHRQ Evidence Report Summaries. Rockville (MD): Agency for Healthcare Research and Quality;2005.

33. Tarlo SM. Standards of care for occupational asthma. Thorax. 2008; 63:190–192.

34. Ye YM, Kim CW, Kim HR, Kim HM, Suh CH, Nahm DH, et al. Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. J Allergy Clin Immunol. 2006; 118:885–891.

35. Vandenplas O, Suojalehto H, Aasen TB, Baur X, Burge PS, de Blay F, et al. Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement. Eur Respir J. 2014; 43:1573–1587.

36. Beretta C, Rifflart C, Evrard G, Jamart J, Thimpont J, Vandenplas O. Assessment of eosinophilic airway inflammation as a contribution to the diagnosis of occupational asthma. Allergy. 2018; 73:206–213.

37. Pralong JA, Lemière C, Rochat T, L'Archevêque J, Labrecque M, Cartier A. Predictive value of nonspecific bronchial responsiveness in occupational asthma. J Allergy Clin Immunol. 2016; 137:412–416.

38. de Groene GJ, Pal TM, Beach J, Tarlo SM, Spreeuwers D, Frings-Dresen MH, et al. Workplace interventions for treatment of occupational asthma: a Cochrane systematic review. Occup Environ Med. 2012; 69:373–374.

39. Vandenplas O, Delwiche JP, Jamart J, Van de Weyer R. Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges. Thorax. 1996; 51:472–478.

40. Engel J, van Kampen V, Lotz A, Abramowski J, Gering V, Hagemeyer O, et al. An increase of fractional exhaled nitric oxide after specific inhalation challenge is highly predictive of occupational asthma. Int Arch Occup Environ Health. 2018; 91:799–809.

41. Walters GI, Moore VC, McGrath EE, Burge S. Fractional exhaled nitric oxide in the interpretation of specific inhalational challenge tests for occupational asthma. Lung. 2014; 192:119–124.

42. Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS). Persistent asthma syndrome after high level irritant exposures. Chest. 1985; 88:376–384.

43. Vandenplas O, Wiszniewska M, Raulf M, de Blay F, Gerth van Wijk R, Moscato G, et al. EAACI position paper: irritant-induced asthma. Allergy. 2014; 69:1141–1153.

44. Siracusa A, De Blay F, Folletti I, Moscato G, Olivieri M, Quirce S, et al. Asthma and exposure to cleaning products - a European Academy of Allergy and Clinical Immunology task force consensus statement. Allergy. 2013; 68:1532–1545.

45. Lipszyc JC, Silverman F, Holness DL, Liss GM, Lavoie KL, Tarlo SM. Comparison of clinic models for patients with work-related asthma. Occup Med (Lond). 2017; 67:477–483.

46. de Olim C, Bégin D, Boulet LP, Cartier A, Gérin M, Lemière C. Investigation of occupational asthma: do clinicians fail to identify relevant occupational exposures? Can Respir J. 2015; 22:341–347.

47. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary [published correction appears in Eur Respir J 2018;51:0751387]. Eur Respir J. 2008; 31:148–178.

48. de Groene GJ, Pal TM, Beach J, Tarlo SM, Spreeuwers D, Frings-Dresen MH, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev. 2011; CD006308.

49. Maestrelli P, Schlünssen V, Mason P, Sigsgaard T. ERS Task Force on the Management of Work-related Asthma. Contribution of host factors and workplace exposure to the outcome of occupational asthma. Eur Respir Rev. 2012; 21:88–96.

50. Lemière C, To T, de Olim C, Ribeiro M, Liss G, Lougheed MD, et al. Outcome of work-related asthma exacerbations in Quebec and Ontario. Eur Respir J. 2015; 45:266–268.

51. Rachiotis G, Savani R, Brant A, MacNeill SJ, Newman Taylor A, Cullinan P. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax. 2007; 62:147–152.

52. Lipszyc JC, Silverman F, Holness DL, Liss GM, Lavoie KL, Tarlo SM. Comparison of psychological, quality of life, work-limitation, and socioeconomic status between patients with occupational asthma and work-exacerbated asthma. J Occup Environ Med. 2017; 59:697–702.

53. Vandenplas O, Henneberger PK. Socioeconomic outcomes in work-exacerbated asthma. Curr Opin Allergy Clin Immunol. 2007; 7:236–241.

54. Larbanois A, Jamart J, Delwiche JP, Vandenplas O. Socioeconomic outcome of subjects experiencing asthma symptoms at work. Eur Respir J. 2002; 19:1107–1113.

55. Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, et al. Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy. 2013; 68:813–815.

56. Caruso C, Gencarelli G, Gaeta F, Valluzzi RL, Rumi G, Romano A. Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic granulomatosis with polyangioitis. Ann Allergy Asthma Immunol. 2018; 120:209–211.

57. Malo JL, L'archevêque J, Castellanos L, Lavoie K, Ghezzo H, Maghni K. Long-term outcomes of acute irritant-induced asthma. Am J Respir Crit Care Med. 2009; 179:923–928.

58. Tarlo SM, Arif AA, Delclos GL, Henneberger P, Patel J. Opportunities and obstacles in translating evidence to policy in occupational asthma. Ann Epidemiol. 2018; 28:392–400.

59. Bernstein DI, Lummus ZL, Kesavalu B, Yao J, Kottyan L, Miller D, et al. Genetic variants with gene regulatory effects are associated with diisocyanate-induced asthma. J Allergy Clin Immunol. 2018; 142:959–969.

60. Yucesoy B, Kashon ML, Johnson VJ, Lummus ZL, Fluharty K, Gautrin D, et al. Genetic variants in TNFα, TGFB1, PTGS1 and PTGS2 genes are associated with diisocyanate-induced asthma. J Immunotoxicol. 2016; 13:119–126.

61. Yucesoy B, Kaufman KM, Lummus ZL, Weirauch MT, Zhang G, Cartier A, et al. Genome-wide association study identifies novel loci associated with diisocyanate-induced occupational asthma. Toxicol Sci. 2015; 146:192–201.

62. Acouetey DS, Zmirou-Navier D, Avogbe PH, Tossa P, Rémen T, Barbaud A, et al. Genetic predictors of inflammation in the risk of occupational asthma in young apprentices. Ann Allergy Asthma Immunol. 2013; 110:423–428.e5.

63. Robitaille C, Boulet LP. Occupational asthma after exposure to ortho-phthalaldehyde (OPA). Occup Environ Med. 2015; 72:381.

64. Seed MJ, Cullinan P, Agius RM. Methods for the prediction of low-molecular-weight occupational respiratory sensitizers. Curr Opin Allergy Clin Immunol. 2008; 8:103–109.

65. Pralong JA, Seed MJ, Yasri R, Agius RM, Cartier A, Labrecque M. A computer based asthma hazard prediction model and new molecular weight agents in occupational asthma. Occup Environ Med. 2013; 70:70.

66. Pacheco KA, Rose CS, Silveira LJ, Van Dyke MV, Goelz K, MacPhail K, et al. Gene-environment interactions influence airways function in laboratory animal workers. J Allergy Clin Immunol. 2010; 126:232–240.

67. North CM, Ezendam J, Hotchkiss JA, Maier C, Aoyama K, Enoch S, et al. Developing a framework for assessing chemical respiratory sensitization: a workshop report. Regul Toxicol Pharmacol. 2016; 80:295–309.

68. Daniels RD. Occupational asthma risk from exposures to toluene diisocyanate: a review and risk assessment. Am J Ind Med. 2018; 61:282–292.

69. Global Initiative for Asthma. 2018 GINA report, global strategy for asthma management and prevention [Internet]. place unknown: Global Initiative for Asthma;2018. cited 2018 Dec 24. Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/.

70. Fishwick D, Forman S. Health surveillance for occupational asthma. Curr Opin Allergy Clin Immunol. 2018; 18:80–86.

71. Suojalehto H, Karvala K, Haramo J, Korhonen M, Saarinen M, Lindström I. Medical surveillance for occupational asthma-how are cases detected? Occup Med (Lond). 2017; 67:159–162.

72. Kraw M, Tarlo SM. Isocyanate medical surveillance: respiratory referrals from a foam manufacturing plant over a five-year period. Am J Ind Med. 1999; 35:87–91.

73. Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med. 2002; 59:58–62.

74. Labrecque M, Malo JL, Alaoui KM, Rabhi K. Medical surveillance programme for diisocyanate exposure. Occup Environ Med. 2011; 68:302–307.